Render Target: STATIC
Render Timestamp: 2024-07-26T10:43:11.244Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

Fetuin A (F180) Antibody #5258

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 45-50
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Fetuin A (F180) Antibody detects endogenous levels of total fetuin A protein.


    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe180 of human fetuin A protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    Fetuin A is produced by liver and secreted to plasma, and selectively concentrated in bone matrix. It is synthesized as a precursor and processed to generate 2 chains that are held together by a disulfide bond. It is a systemically acting calcification inhibitor (1). Reduced level of fetuin A in serum is associated with increased cardiovascular mortality in dialysis patients (2,3). Fetuin A can inhibit insulin-induced tyrosine phosphorylation of the insulin receptor tyrosine kinase and insulin receptor substrate-1 (4). Fetuin A deficient mice show high insulin sensitivity and high levels of serum fetuin A are associated with insulin resistance in humans (5,6).

      For Research Use Only. Not For Use In Diagnostic Procedures.
      Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
      All other trademarks are the property of their respective owners. Visit our Trademark Information page.